Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bone Biologics Zack’s Small Cap Research Issues Note With $8 Valuation Target On Stock

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03182022_BBLG_Sorensen.pdf

byBenzinga Newsdesk

March 18, 2022

1 minute read

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03182022_BBLG_Sorensen.pdf

Benchmark Maintains Buy on Cross Country Healthcare, Raises Price Target to $40

By Benzinga Newsdesk

February 23, 10:54 AM

Benchmark analyst Bill Sutherland maintains Cross Country Healthcare (NASDAQ:CCRN) with a Buy and raises the price target from $45 to $40.

CCRN

NFT Possibilities For Disney Are ‘Extraordinary’: How Bob Iger’s Return Could Propel Web3 Growth

By Chris Katje

November 21, 12:08 PM

With recent struggles for The Walt Disney Company (NYSE: DIS), a former CEO is being brought in to help steer the company forward. Could that next phase of growth include a deeper connection in the world of Web3?

COIN

Analyst Ratings

Expert Ratings For Ambarella

By Benzinga Insights

October 27, 12:23 PM

Ambarella (NASDAQ:AMBA) has observed the following analyst ratings within the last quarter:

AMBA

Lululemon To Surge Over 20%? Plus Wedbush Predicts $370 For Domino’s

By Lisa Levin

October 11, 7:09 AM

Piper Sandler raised Lululemon Athletica Inc. (NASDAQ: LULU) price target from $320 to $350. Lululemon shares fell 2.8% to close at $289.85 on Monday.

DPZ

Bone Biologics Zack’s Small Cap Research Issues Note With $8 Valuation Target On Stock

Related Posts

Benchmark Maintains Buy on Cross Country Healthcare, Raises Price Target to $40

NFT Possibilities For Disney Are ‘Extraordinary’: How Bob Iger’s Return Could Propel Web3 Growth

Expert Ratings For Ambarella

Lululemon To Surge Over 20%? Plus Wedbush Predicts $370 For Domino’s